CLINICAL ROLE -
Clinical Overview: Fecal Microbiota Transplantation vs Live Biotherapeutic Products for Management of Recurrent C Difficile Infection
Although antibiotics are the standard-of-care treatment for Clostridioides difficile infection, they can cause further microbiota changes that predispose patients to recurrence.
Read More
Clinical Overview: Steps to Implementation of Rebyota for Recurrent C difficile Infection
Rebyota is a live biotherapeutic product that is unfamiliar to many pharmacists and other health care providers with different steps in the eventual administration process.
Bacteroidetes: The Jekyll and Hyde of the Human Gut Microbiome
The relative abundance of gram-negative Bacteroidetes to other phyla, such as gram-positive Firmicutes, is essential to maintain biodiversity and human gut health.
The Ins and Outs of Fecal Microbiota Transplantation Administration
Fecal microbiota transplantation is proving to be an effective treatment for many patients with specific disorders associated with dysbiosis.
Unrecognized Costs Associated With Clostridium Difficile Infection: What HCPs Often Miss
From an economic perspective, C. difficile has a staggering financial impact on the US health care system, as well on the patients infected.
Transitions of Care in Patients With Recurrent C. Diff: An Opportunity for Collaboration Among Community, Health System Pharmacists
Approximately 450,000 cases of Clostridioides difficile infection occur each year in the United States and approximately 25% of patients treated for an initial episode will experience recurrence.
